Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Concordia International Corp. (NASDAQ: CXRX).

Full DD Report for CXRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: CXRX)

Concordia International Corp. Announces Filing of its Information Circular in connection with its Recapitalization Transaction and its Annual Meeting of Shareholders
Concordia International Corp. Announces Filing of its Information Circular in connection with its Recapitalization Transaction and its Annual Meeting of Shareholders Canada NewsWire OAKVILLE, ON, May 17, 2018 OAKVILLE, ON , May 17, 2018 /CNW/ - Concordia Internationa...
Source: Canada Newswire
Date: May, 17 2018 16:47
Concordia International's (CXRX) CEO Graeme Duncan on Q1 2018 Results - Earnings Call Transcript
Concordia International Corp. (CXRX) Q1 2018 Earnings Conference Call May 15, 2018 8:30 AM ET Executives Adam Peeler - Vice President, Investor Relations and Corporate Communications Graeme Duncan - Interim Chief Executive Officer David Price - Chief Financial Officer Presenta...
Source: SeekingAlpha
Date: May, 15 2018 10:18
Concordia International down 7% on Q1 result
Concordia International ( CXRX +5.7% ) Q1 results : Revenues: $152.3M (-5.2%); Operating Loss: ($11.2M); Net Loss: ($55.7M) (+29.3%); Loss Per Share: ($1.09) (+29.2%); Quick Assets: $344M; CF Ops: $51M. More news on: Concordia International Corp, Healthcare stocks news, Earnings news an...
Source: SeekingAlpha
Date: May, 15 2018 08:50
Concordia International reports Q1 results
Concordia International (NASDAQ: CXRX ): Q1 EPS of -$1.09 More news on: Concordia International Corp, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 15 2018 07:01
Concordia International Corp. Announces First Quarter 2018 Results
Concordia International Corp. Announces First Quarter 2018 Results Canada NewsWire OAKVILLE, ON, May 15, 2018 First quarter 2018 revenue of $152 million First quarter 2018 GAAP net loss of $56 million First quarter 2018 adjusted EBITDA 1 of $72 million ...
Source: Canada Newswire
Date: May, 15 2018 07:00
Concordia International Corp. Announces Release Date for First Quarter 2018 Results
Concordia International Corp. Announces Release Date for First Quarter 2018 Results Canada NewsWire OAKVILLE, ON, May 7, 2018 OAKVILLE, ON , May 7, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international s...
Source: Canada Newswire
Date: May, 07 2018 17:00
Concordia continues recapitalization-stoked selloff, down 5%
Thinly traded nano cap Concordia International ( CXRX -4.7% ) continues its slide on almost triple normal volume, albeit on turnover of only 348K shares. The stock has sold off almost  45%  this week in response to its deal with creditors to recapitalize its debt that virtually...
Source: SeekingAlpha
Date: May, 04 2018 14:02
Concordia International Corp. Executes Support Agreement and Obtains Interim Order in Connection with its Recapitalization Transaction, and Announces Leadership Transition
Concordia International Corp. Executes Support Agreement and Obtains Interim Order in Connection with its Recapitalization Transaction, and Announces Leadership Transition Canada NewsWire OAKVILLE, ON, May 2, 2018 Concordia announces the execution of a support agreement wi...
Source: Canada Newswire
Date: May, 02 2018 08:58
Wired News - FDA Approved Intra-Cellular's Rolling NDA Submission for Lumateperone for Schizophrenia
Stock Monitor: Concordia Intl. Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 15, 2018 / Active-Investors.com has just released a free research report on Intra-Cellular Therapies, Inc. (NASDAQ: ITCI ) (“Intra-Cellular”). If you want access to this report all yo...
Source: ACCESSWIRE IA
Date: March, 15 2018 07:50
Wired News - Biogen Presented New Interim Phase-2 Results from NURTURE Evaluating Efficacy and Safety of SPINRAZA at MDA Clinical Conference
Stock Monitor: Concordia Intl. Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 14, 2018 / Active-Investors.com has just released a free research report on Biogen Inc. (NASDAQ: BIIB ).If you want access to this report all you need to do is sign up now by clicking the following...
Source: ACCESSWIRE IA
Date: March, 14 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-06-14N/A0.19N/AN/A0
2018-06-13N/A0.19N/AN/A0
2018-06-12N/A0.19N/AN/A0
2018-06-11N/A0.19N/AN/A0
2018-06-08N/A0.19N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-06-076,29684,1807.4792Cover
2018-06-0615,63365,01124.0467Cover
2018-06-0533,384177,33718.8252Cover
2018-06-0435,617230,76815.4341Cover
2018-06-0116,334105,00115.5560Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CXRX.


About Concordia International Corp. (NASDAQ: CXRX)

Logo for Concordia International Corp. (NASDAQ: CXRX)

Concordia Healthcare Corporation is a diverse healthcare company focused on the acquisition of legacy pharmaceutical products, medical devices and orphan drugs.

 

Contact Information

 

 

Current Management

  • Mark L. Thompson / President, CEO
  • Wayne Kreppner / COO
  • Adrian de Saldanha / CFO
  • Ron Schmeichel / Chairman
  • Doug Deeth /
  • John Huss /
  • Jordan Kupinsky /
  • Paul Manning /
  • Mark L. Thompson /

Current Share Structure

  • Market Cap: $9,425,209 - 05/15/2018
  • Issue and Outstanding: 28,561,239 - 10/15/2014
  • Float: 11,458,228 - 01/07/2014

 


Recent Filings from (NASDAQ: CXRX)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 16 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 15 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 10 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 08 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 07 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 04 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 02 2018
Annual and transition report of foreign private issuers under sections 13 or 15(d)
Filing Type: 20-FFiling Source: edgar
Filing Date: March, 08 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 08 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 21 2018

 

 


Daily Technical Chart for (NASDAQ: CXRX)

Daily Technical Chart for (NASDAQ: CXRX)


Stay tuned for daily updates and more on (NASDAQ: CXRX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CXRX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CXRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CXRX and does not buy, sell, or trade any shares of CXRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/